Months after the FDA sanctioned the approval of Roche’s runner up checkpoint inhibitor Tecentriq in combination with Celgene’s Abraxane for treatment naive patients with triple negative breast cancer, Merck’s keynote PD-1 Keytruda has stumbled in a late-stage trial as the second or third line of defense against the rare, aggressive form of cancer. Patients in … Continue reading Merck’s Keytruda fails triple negative breast cancer pivotal study